Royal Philips and PathAI, a pathology-focused artificial intelligence company, partnered to improve breast cancer diagnosis.
The organizations are applying deep learning applications to pathology data sets to inform diagnosis and treatment decisions related to cancer. Their initial goal is to develop software that automatically detects cancerous lesions in breast cancer tissue.
Philips and PathAI say this decision support tool will help reduce pathologists' workloads.
"Identifying the presence or absence of cancer in lymph nodes is a routine and critically important task for a pathologist," said Andy Beck, CEO of PathAI. "However, it can be extremely laborious using conventional methods. Research indicates that pathologists supported with computational tools could be both more accurate and faster."